
Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation
pharmafile | July 11, 2019 | News story | Sales and Marketing | Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma
Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after the Scottish Medicines Consortium chose to recommend the therapy in combination with fulvestrant for the treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in patients who have received prior endocrine treatment.
The decision was based on Phase 3 data supporting the efficacy of the combo therapy in the recommended indication; it is thought that around 400 patients in Scotland will be eligible to it.
“We are delighted with today’s news from the SMC. Treating women with palbociclib and fulvestrant has been found to be an important and effective option for those who have already received earlier rounds of hormone therapy and we are pleased that this combination of medicines will now be routinely available in Scotland,” commented Dr Olivia Ashman, Oncology Medical Director at Pfizer UK. “We know that this approval from the SMC will be meaningful for the many patients and families who are affected by this type of advanced breast cancer and we hope the same outcome will be reached by NICE later this year.”
NICE, which assesses the availability of medicines to NHS patients in England and Wales, is currently working through its own appraisal for the therapy, and is expected to reach a decision before the end of the year.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Major funding opportunity opens for early cancer diagnostics
Up to £25.4m in funding is available for collaborative projects developing technologies to improve the …






